Patents Assigned to Cancer Institute and Hospital
  • Publication number: 20240254560
    Abstract: An application of feature gene TRIM22 in preparing reagent for regulating expression of breast cancer-related genes is provided. The feature gene TRIM22 disclosed in the present disclosure upregulates the expression of breast cancer-related genes SIX3, GATA6, PTX3, MMP1 and DMBT1 through overexpression, and downregulates the expression of the breast cancer-related genes SOX4, CXCL10, TNF, TP63 and CXCL16 through overexpression. Therefore, the feature gene TRIM22 provided in the present disclosure can be used as a reagent product to regulate the expression of breast cancer-related genes GATA6, SIX3, SOX4, CXCL10, PTX3, TNF, TP63, MMP1, CXCL16 and DMBT1 through overexpression.
    Type: Application
    Filed: February 1, 2024
    Publication date: August 1, 2024
    Applicant: Cancer Institute and Hospital
    Inventors: Yan WANG, Baowen YUAN, Wei HUANG, Hefen YU, Jingyao ZHANG, Yunkai YANG
  • Patent number: 10512627
    Abstract: The invention disclose a compound of formula (I), wherein, R1 is selected from —H or C1-C6 hydrocarbon group, —NH2, —OH, —O(CH2)nCH3 (n=0, 1 or 2), —N(CH3)2, or —CH2N(CH3)2, R2 is selected from an amino acid or an hydroxy acid or —OH (R1, R2 are not —CH3 and —OH at the same time), wherein X, Y are —H, —CH3, —CH2OH, —CH(OH)CH3, —CH2SH, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH3)CH2CH3, —CH2CH2SCH3, —CH2COOH, —CH2CONH2, —CH2CH2COOH, —CH2CH2CH2CH2NH2, or —CH2CH2CONH2, R3-R5 are H or C1-C6 hydrocarbon group. The compound has a low toxicity, can significantly inhibit the migration and invasion of tumor cells in vitro, and can inhibit tumor metastasis in vivo in mice at low concentration, while showing notable sensitizing effect on cytotoxic anti-tumor drugs such as Paclitaxel etc.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: December 24, 2019
    Assignee: Tianjin Medical University Cancer Institute and Hospital
    Inventors: Ning Zhang, Yinsong Wang, Ping Zhou, Hua Guo, Yi Luo, Xishan Hao, Hua Geng
  • Patent number: 5968973
    Abstract: A method for a treatment of hyperplasia caused by papilloma virus, such as for treating Condyloma acuminata which comprises administering tea catechin. Tea catechins do not involve the risk of side-effects and may be easily applied to or inserted in the infected area by the patients themselves.
    Type: Grant
    Filed: April 7, 1998
    Date of Patent: October 19, 1999
    Assignees: Cancer Institute (Hospital), Chinese Academy of Medical Sciences, Mitsui Norin Co., Ltd.
    Inventors: Shu Jun Cheng, De Chang Wang, Yukihiko Hara
  • Patent number: 5804567
    Abstract: A method for treating cancer in a patient by administering to a patient an nti-cancer effective amount of an anti-metabolite selected from the group consisting of 1-.beta.-arabinofuranosylcytosine and 4-amino-4-deoxy-10-methylfolic acid and an anti-oxidant effective amount of a tea polyphenol compound selected from the group consisting of a tea catechin, a theaflavin and a combination of a tea catechin and a theaflavin.
    Type: Grant
    Filed: August 27, 1997
    Date of Patent: September 8, 1998
    Assignees: Cancer Institute (Hospital), Chinese Academy of Medical Sciences, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Mitsui Norin Co., Ltd.
    Inventors: Shu Jun Cheng, De Chang Wang, Yong Su Zhen, Hoyoku Nishino, Yukihiko Hara
  • Patent number: 5795911
    Abstract: A composition for a treatment of HPV-infected Condyloma acuminata which comprises containing tea catechin as a main component. This medication has no danger of side-effects and may be easily applied to or inserted in the infected area by the patient themselves.
    Type: Grant
    Filed: April 10, 1997
    Date of Patent: August 18, 1998
    Assignees: Cancer Institute (Hospital), Chinese Academy of Medical Sciences, Mitsui Norin Co., Ltd.
    Inventors: Shu Jun Cheng, De Chang Wang, Yukihiko Hara